DOCSLIB.ORG

Cinacalcet Accordpharma, INN-Cinacalcet

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cinacalcet Accordpharma, INN-Cinacalcet 30 January 2020 EMA/92635/2020 Committee for Medicinal Products for Human Use (CHMP) Assessment report Cinacalcet Accordpharma International non-proprietary name: cinacalcet Procedure No. EMEA/H/C/005236/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. Downloaded from wizmed.com Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us Send us a question Go to www.ema.europa.eu/contact Telephone +31 (0)88 781 6000 An agency of the European Union © European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged. Table of contents 1. Background information on the procedure .............................................. 7 1.1. Submission of the dossier ...................................................................................... 7 1.2. Steps taken for the assessment of the product ......................................................... 9 2. Scientific discussion .............................................................................. 10 2.1. Introduction....................................................................................................... 10 2.1.1. Problem statement .......................................................................................... 10 2.1.2. About the product ............................................................................................ 10 2.1.3. The development programme/compliance with CHMP guidance/scientific advice ...... 11 2.2. Quality aspects .................................................................................................. 11 2.2.1. Introduction .................................................................................................... 11 2.2.2. Active Substance ............................................................................................. 11 General Information .............................................................................................. 11 Manufacture, process controls and characterisation .............................................. 12 Stability ................................................................................................................. 14 2.2.3. Finished Medicinal Product ................................................................................ 14 Description of the product and Pharmaceutical Development ................................. 14 Product specification, analytical procedures, batch analysis .................................. 17 Adventitious agents ............................................................................................... 18 2.2.4. Discussion on chemical, and pharmaceutical aspects ............................................ 18 2.2.5. Conclusions on the chemical, pharmaceutical and biological aspects ...................... 18 2.2.6. Recommendations for future quality development................................................ 18 2.3. Non-clinical aspects ............................................................................................ 19 2.3.1. Introduction .................................................................................................... 19 2.3.2. Ecotoxicity/environmental risk assessment ......................................................... 19 2.3.3. Discussion on non-clinical aspectsDownloaded................................ from wizmed.com ...................................... 19 2.3.4. Conclusion on non-clinical aspects ..................................................................... 19 2.4. Clinical aspects .................................................................................................. 19 2.4.1. Introduction .................................................................................................... 19 2.4.2. Pharmacokinetics............................................................................................. 21 Methods .................................................................................................................. 21 Study design ............................................................................................................ 21 Test and reference products ....................................................................................... 22 Population(s) studied ................................................................................................ 22 Analytical methods .................................................................................................... 24 Pharmacokinetic Variables.......................................................................................... 24 Statistical methods ................................................................................................... 24 Results .................................................................................................................... 25 Safety data .............................................................................................................. 27 2.4.3. Pharmacokinetic Conclusion .............................................................................. 28 2.4.4. Pharmacodynamics .......................................................................................... 28 2.4.5. Post-marketing experience ............................................................................... 28 2.4.6. Discussion on clinical aspects ............................................................................ 29 Assessment report EMA/92635/2020 Page 2/33 2.4.7. Conclusions on clinical aspects .......................................................................... 29 2.5. Risk Management Plan ........................................................................................ 29 2.6. Pharmacovigilance .............................................................................................. 31 2.7. Product information ............................................................................................ 31 2.7.1. User consultation ............................................................................................. 31 3. Benefit-Risk Balance.............................................................................. 31 4. Recommendations ................................................................................. 31 Downloaded from wizmed.com Assessment report EMA/92635/2020 Page 3/33 List of abbreviations AAS: Atomic Absorption Spectrometry AE Adverse event ANIOVA Analysis of variances AP: Applicant's Part (or Open Part) of a ASMF API: Active Pharmaceutical Ingredient AR: Assessment Report AS: Active substance ASM: Active Substance Manufacturer ASMF: Active Substance Master File ATC Anatomical therapeutic chemical (classification system) AUC Area under the plasma concentration versus time curve BCS: Biopharmaceutics classification system BE: Bioequivalence BE Guideline: Guideline on the Investigation of Bioequivalence (CPMP/EWP/QWP/1401/98 Rev 01 – January 2010) BMD Bone mineral density BQL: Below quantification limit BSE: Bovine spongiform encephalopathy Ca Calcium Ca x P Calcium-phosphorus product CAC Coronary artery calcification CaR Calcium-sensing receptor CFU: Colony-forming unit CI Confidence interval CKD Chronic kidney disease Downloaded from wizmed.com CLcr Creatinine clearance Cmax Maximal (peak) plasma concentration CoA: Certificate of analysis CV Coefficient of variation CYP Cytochrome P450 DPM: Drug Product Manufacturer DSC: Differential scanning calorimetry EC50 Effective concentration 50% EMA European Medicines Agency ESRD End-stage renal disease EU European Union EU: European Union Fct: Film coated tablet FDA Food and Drug Administration FGF Fibroblast growth factor Assessment report EMA/92635/2020 Page 4/33 FHH Familial hypocalciuric hypocalcaemia GC Gas chromatography GCP Good Clinical Practice GFR glomerular filtration rate GMP: Good Manufacturing Practice GVP Good Pharmacovigilance Practice HCL Hydrochloride HDPE: High Density Polyethylene HIV Human immunodeficiency virus HPLC: High Performance Liquid Chromatography HPT Hyperparathyroidism HR hazard ratio IC50 Inhibitory concentration 50% ICH: International Conference on Harmonisation INN International Nonproprietary Name IPC: In-process controls iPTH Intact parathyroid hormone IR: Infra-Red Spectroscopy IV intravenous(ly) JECFA: Joint Evaluation Committee on Food Additives JP MO: Japanese Ministerial Ordinance JPE: Japanese Pharmaceutical Excipients KDOQI Kidney Disease Outcome Quality Initiative Kel Elimination constant LDPE: Low Density Polyethylene LOD: Limit of Detection Downloaded from wizmed.com LOQ: Limit of Quantitation LoQ: List of Questions LSmean Least square mean MAH marketing authorization holder MAPK Mitogen-activated protein kinase MedDRA Medical Dictionary for Regulatory Activities N/A Not applicable ND: Not detected NLT: Not Less Than NMR: Nuclear Magnetic Resonance NMT Not More Than P Phosphorus PD peritoneal dialysis PE: Polyethylene Ph.Eur. European Pharmacopoeia Assessment report EMA/92635/2020 Page 5/33 PIL: Patient Information Leaflet PP: Polypropylene primary HPT primary hyperparathyroidism pmarp per million of the age-related population pmp per million population PRT post-renal transplant PSUR periodic safety update report PTH parathyroid hormone PY patient years PVC: Poly vinyl chloride QOS: Quality Overall Summary QP: Qualified Person QPPV Qualified Person for Pharmacovigilance
Load more

Recommended publications
  • Teriparatide Injection I.P. (R-DNA Origin) Interactions Were Noted
    PA011FSRI04 For more information, visit us at www.lillyindia.co.in Interactions with other medicinal products and other forms of interaction Forteo® has been evaluated in pharmacodynamic interaction studies with hydrochlorothiazide. No clinically significant Teriparatide Injection I.P. (r-DNA origin) interactions were noted. ® Co-administration of raloxifene or hormone replacement therapy with Forteo® did not alter the effects of Forteo® on Forteo serum or urine calcium or on clinical adverse events. (600mcg/2.4mL, Solution for injection in a pre-filled pen) In a study of 15 healthy subjects administered digoxin daily to steady state, a single Forteo® dose did not alter the cardiac effect of digoxin. However, sporadic case reports have suggested that hypercalcaemia may predispose patients to digitalis toxicity. Because Forteo® transiently increases serum calcium, Forteo® should be used with caution in patients taking digitalis NAME OF THE MEDICINAL PRODUCT Fertility, pregnancy and lactation Fertility Forteo® 600mcg/2.4mL, solution for injection, in pre-filled pen. Studies in rabbits have shown reproductive toxicity (see section Preclinical safety data). The effect of teriparatide on human foetal development has not been studied. The potential risk for humans is unknown. QUALITATIVE AND QUANTITATIVE COMPOSITION Pregnancy Each mL of Teriparatide Injection I.P. contains: 250 mcg Teriparatide I.P. (r-DNA origin) as active ingredient, Forteo® is contraindicated for use during pregnancy (see section Contraindications) 0.41 mg Glacial Acetic Acid I.P. as buffering agent, 0.10 mg Sodium Acetate (Anhydrous) I.P. as buffering agent, Breast –Feeding 45.4 mg Mannitol I.P. as tonicity modifier, 3.0 mg Metacresol Ph.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Estonian Statistics on Medicines 2016 1/41
    Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole
    [Show full text]
  • Innovationsreport 2020 Kurzfassung
    Innovationsreport 2020 Auswertungsergebnisse von Routinedaten der Techniker Krankenkasse aus den Jahren 2017 bis 2018 Herausgeber: Gerd Glaeske Erstellt mit freundlicher Unterstützung der Techniker Krankenkasse (TK) 3 Herausgeber Prof. Dr. Gerd Glaeske Experten für ausgewählte Kapitel Prof. Dr. med. Janbernd Kirschner, Bonn Prof. Dr. med. Dieter Ukena, Bremen Prof. Dr. med. Barbara Schmalfeldt, Hamburg Prof. Dr. med. Wolfgang Schramm, München Autoren Prof. Dr. med. Karl Broich, Dr. Stanislava Dicheva‐Radev, Dörte Fuchs, Prof. Dr. Gerd Glaeske, Dr. Marion Haberkamp, Dr. Iris Hinneburg, Friederike Höfel, Prof. Dr. Janbernd Kirschner, Dr. Wiebke Löbker, Anja Lübs, Dr. André S. Morawetz, Lutz Muth, Dr. Frauke Naumann‐Winter, Linda Richter, Saskia Ritter, Dr. Kristin Sauer, Dr. Birgit Schindler unter Mitarbeit von Esra Aksoy, Friederike Höfel, Berit Marquardt, Linda Richter, Marle Wilhelm Anschrift: Universität Bremen, SOCIUM, Mary‐Somerville‐Str. 5, 28359 Bremen Aus Gründen der besseren Lesbarkeit wurde auf die Nennung beider geschlechtsspezifischer Formen verzichtet. Im Allgemeinen ist aber das jeweils andere Geschlecht ebenfalls gemeint. 2 Glossar .......................................................................................... 7 Vorwort zum Innovationsreport 2020 ...........................................15 Vorwort des Herausgebers ............................................................17 1 Einleitung ................................................................................19 2 Ziele und Methodik..................................................................33
    [Show full text]
  • Drug Consumption in Current Year (Period 201901
    Page 1 Drug consumption in current year (Period 202001 - 202012) Wholesale ATC code Subgroup or chemical substance DDD/1000 inhab./day Hospital % Change % price/1000 € Hospital % Change % A ALIMENTARY TRACT AND METABOLISM 323,80 3 4 321 589 7 4 A01 STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01A STOMATOLOGICAL PREPARATIONS 14,28 4 12 2 090 9 8 A01AA Caries prophylactic agents 11,90 3 14 663 8 9 A01AA01 sodium fluoride 11,90 3 14 610 8 10 A01AA03 olaflur - - - 53 1 -2 A01AB Antiinfectives for local oral treatment 2,36 8 2 1 266 10 15 A01AB03 chlorhexidine 2,02 6 -3 930 6 5 A01AB11 various 0,33 21 57 335 21 55 A01AB22 doxycycline - - - 0 - -100 A01AC Corticosteroids for local oral treatment - - - 113 1 -26 A01AC01 triamcinolone - - - 113 1 -26 A01AD Other agents for local oral treatment 0,02 0 -28 49 0 -32 A01AD02 benzydamine 0,02 0 -28 49 0 -32 A02 DRUGS FOR ACID RELATED DISORDERS 73,05 3 3 30 885 4 -5 A02A ANTACIDS 2,23 1 1 3 681 1 3 A02AA Magnesium compounds 0,07 22 -7 141 22 -7 A02AA04 magnesium hydroxide 0,07 22 -7 141 22 -7 A02AD Combinations and complexes of aluminium, 2,17 0 1 3 539 0 4 calcium and magnesium compounds A02AD01 ordinary salt combinations 2,17 0 1 3 539 0 4 A02B DRUGS FOR PEPTIC ULCER AND 70,82 3 3 27 205 5 -7 GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 0,17 7 -77 551 10 -29 A02BA02 ranitidine 0,00 1 -100 1 1 -100 A02BA03 famotidine 0,16 7 48 550 10 43 A02BB Prostaglandins 0,04 62 55 80 62 55 A02BB01 misoprostol 0,04 62 55 80 62 55 A02BC Proton pump inhibitors 69,26 3 4 23 531 4 -8
    [Show full text]
  • ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 Is Available in Electronic Format on the PMPRB Website
    MEDS ENTRY WATCH 2016 Published by the Patented Medicine Prices Review Board June 2018 Meds Entry Watch, 2016 is available in electronic format on the PMPRB website. Une traduction de ce document est également disponible en français sous le titre : Veille des médicaments mis en marché, 2016 Patented Medicine Prices Review Board Standard Life Centre Box L40 333 Laurier Avenue West Suite 1400 Ottawa, ON K1P 1C1 Tel.: 1-877-861-2350 TTY 613-288-9654 Email: [email protected] Web: www.pmprb-cepmb.gc.ca ISSN 2560-6204 Cat. No.: H79-12E-PDF © Her Majesty the Queen in Right of Canada, as represented by the NPDUIS initiative of the Patented Medicine Prices Review Board, 2018 MEDS ENTRY WATCH 2016 About the PMPRB Acknowledgements The Patented Medicine Prices Review Board This report was prepared by the Patented (PMPRB) is a respected public agency that makes Medicine Prices Review Board (PMPRB) a unique and valued contribution to sustainable as part of the National Prescription Drug spending on pharmaceuticals in Canada by: Utilization Information System (NPDUIS). ~ providing stakeholders with price, cost and The PMPRB would like to acknowledge the utilization information to help them make timely contributions of and knowledgeable drug pricing, purchasing and ~ The members of the NPDUIS Advisory reimbursement decisions; and Committee for their expert oversight and ~ acting as an effective check on the patent rights guidance in the preparation of this report. of pharmaceutical manufacturers through the ~ PMPRB NPDUIS staff for their contribution responsible and efficient use of its consumer to the analytical content of the report: protection powers.
    [Show full text]
  • Drug Consumption at Wholesale Prices in 2017 - 2020
    Page 1 Drug consumption at wholesale prices in 2017 - 2020 2020 2019 2018 2017 Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. Wholesale Hospit. ATC code Subgroup or chemical substance price/1000 € % price/1000 € % price/1000 € % price/1000 € % A ALIMENTARY TRACT AND METABOLISM 321 590 7 309 580 7 300 278 7 295 060 8 A01 STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01A STOMATOLOGICAL PREPARATIONS 2 090 9 1 937 7 1 910 7 2 128 8 A01AA Caries prophylactic agents 663 8 611 11 619 12 1 042 11 A01AA01 sodium fluoride 610 8 557 12 498 15 787 14 A01AA03 olaflur 53 1 54 1 50 1 48 1 A01AA51 sodium fluoride, combinations - - - - 71 1 206 1 A01AB Antiinfectives for local oral treatment 1 266 10 1 101 6 1 052 6 944 6 A01AB03 chlorhexidine 930 6 885 7 825 7 706 7 A01AB11 various 335 21 216 0 227 0 238 0 A01AB22 doxycycline - - 0 100 0 100 - - A01AC Corticosteroids for local oral treatment 113 1 153 1 135 1 143 1 A01AC01 triamcinolone 113 1 153 1 135 1 143 1 A01AD Other agents for local oral treatment 49 0 72 0 104 0 - - A01AD02 benzydamine 49 0 72 0 104 0 - - A02 DRUGS FOR ACID RELATED DISORDERS 30 885 4 32 677 4 35 102 5 37 644 7 A02A ANTACIDS 3 681 1 3 565 1 3 357 1 3 385 1 A02AA Magnesium compounds 141 22 151 22 172 22 155 19 A02AA04 magnesium hydroxide 141 22 151 22 172 22 155 19 A02AD Combinations and complexes of aluminium, 3 539 0 3 414 0 3 185 0 3 231 0 calcium and magnesium compounds A02AD01 ordinary salt combinations 3 539 0 3 414 0 3 185 0 3 231 0 A02B DRUGS FOR PEPTIC ULCER AND 27 205 5 29 112 4 31 746 5 34 258 8
    [Show full text]
  • Estonian Statistics on Medicines 2013 1/44
    Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)
    [Show full text]
  • Forsteo, INN-Teriparatide
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 1. NAME OF THE MEDICINAL PRODUCT FORSTEO 20micrograms/80 microliters, solution for injection, in pre-filled pen . 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One pre-filled pen of 3 ml contains 750 micrograms of teriparatide (corresponding to 250 micrograms per ml). Each dose contains 20 micrograms of teriparatide. The pre-filled pen is intended for 28 days of dosing. Teriparatide, rhPTH(1-34), (FORSTEO), produced in E. coli, using recombinant DNA technology, is identical to the 34 N-terminal amino acid sequence of endogenous human parathyroid hormone. For excipients, see 6.1 3. PHARMACEUTICAL FORM Solution for injection in a pre-filled pen. Colourless, clear solution. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of established osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. 4.2 Posology and method of administration The recommended dose of FORSTEO is 20 micrograms administered once daily by subcutaneous injection in the thigh or abdomen. Patients must be trained to use the proper injection techniques (see section 6.6). A User Manual is also available to instruct patients on the correct use of the pen. The maximum total duration of treatment with FORSTEO should be 18 months (see section 4.4 Special warnings and special precautions for use). Patients should receive supplemental Calcium and vitamin D supplements if dietary intake is inadequate. Following cessation of FORSTEO therapy, patients may be continued on other osteoporosis therapies. Use in renal impairment: FORSTEO should not be used in patients with severe renal impairment (see 4.3.
    [Show full text]
  • Reseptregisteret 2014–2018 the Norwegian Prescription Database 2014–2018
    LEGEMIDDELSTATISTIKK 2019:2 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Reseptregisteret 2014–2018 The Norwegian Prescription Database 2014–2018 Christian Lie Berg Kristine Olsen Solveig Sakshaug Utgitt av Folkehelseinstituttet / Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2019 Tittel/Title: Legemiddelstatistikk 2019:2 Reseptregisteret 2014–2018 / The Norwegian Prescription Database 2014–2018 Forfattere/Authors: Christian Berg, redaktør/editor Kristine Olsen Solveig Sakshaug Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no / The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon / Contact information: Folkehelseinstituttet / Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8406-014-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2014–2018 [The Norwegian Prescription Database 2014–2018] Legemiddelstatistikk 2019:2, Oslo, Norge: Folkehelseinstituttet, 2019. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian
    [Show full text]
  • Evaluation of Carcinogenicity Studies of Medicinal Products for Human Use Authorised Via the European Centralised Procedure
    Regulatory Toxicology and Pharmacology xxx (2011) xxx–xxx Contents lists available at ScienceDirect Regulatory Toxicology and Pharmacology journal homepage: www.elsevier.com/locate/yrtph Evaluation of carcinogenicity studies of medicinal products for human use authorised via the European centralised procedure (1995–2009) ⇑ Anita Friedrich a, , Klaus Olejniczak b a Granzer Regulatory Consulting and Services, Zielstattstrasse 44, 81379 Munich, Germany b Federal Institute for Drugs and Medical Devices, Kurt-Georg-Kiesinger-Allee 3, 53175 Bonn, Germany article info abstract Article history: Carcinogenicity data of medicinal products for human use that have been authorised via the European Received 25 October 2010 centralised procedure (CP) between 1995 and 2009 were evaluated. Carcinogenicity data, either from Available online xxxx long-term rodent carcinogenicity studies, transgenic mouse studies or repeat-dose toxicity studies were available for 144 active substances contained in 159 medicinal products. Out of these compounds, 94 Keywords: (65%) were positive in at least one long-term carcinogenicity study or in repeat-dose toxicity studies. Medicinal products Fifty compounds (35%) showed no evidence of a carcinogenic potential. Out of the 94 compounds with Carcinogenicity positive findings in either carcinogenicity or repeat-dose toxicity studies, 33 were positive in both mice Rodents and rats, 40 were positive in rats only, and 21 were positive exclusively in mice. Long-term carcinogenic- ity studies in two rodent species were available for 116 compounds. Data from one long-term carcinoge- nicity study in rats and a transgenic mouse model were available for eight compounds. For 13 compounds, carcinogenicity data were generated in only one rodent species. One compound was exclu- sively tested in a transgenic mouse model.
    [Show full text]
  • National Licensed Medicine List of Afghanistan
    islamic republic of afghanistan ministry of public health general directorate of pharmaceutical affairs avicenna pharmaceutical institute National Licensed Medicine List of Afghanistan 2014 2 NATIONAL LICENSED MEDICINES LIST OF AFGHANISTAN Preface With thanks to God for enabling us, we present this revision of the national essential medicines list (EML) and the licensed medicines list (LML) of Afghanistan. These documents are critical to the delivery of quality health services across the country. The policy of the Ministry of Public Health (MoPH) of the Islamic Republic of Afghanistan includes ensuring that the population of Afghanistan has access to safe, effective, and affordable medicines to treat its primary health problems. The EML includes the medicines needed for adequately addressing the priority health problems defined in the MoPH’s health strategy. The LML includes the medicines listed in the EML and additional medicines for conditions not included as priorities in the present strategy and medicines used in private sector. The MoPH developed and published the national EML of Afghanistan for the first time in 1995 and the LML in 2003; the last revision and publication occurred in 2007. The EML and LML should be revised regularly in response to the rapid expansion of basic health services in Afghanistan since 2003, the changing of internationally and nationally recommended treatment protocols for some diseases, the presence of new and emergent diseases, and the withdrawal of some toxic medicines from treatment guidelines. To revise the EML and LML, the MoPH authorized the National Medicine Selection Committee (NMSC) to develop a detailed procedure for inclusion or exclusion of medicines from the 2007 lists.
    [Show full text]